Tri Ri Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Tri Ri Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$8.73M	Buy	+18,762	New	+$9.01M	4.42%	7

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Tri Ri Asset Management's VRTX Position: Q3 2024 in Review

Tri Ri Asset Management opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2024: 18,762 shares worth $8.73M. The stake represents 4.42% of the portfolio and ranks #7 among its holdings.

1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

Tri Ri Asset Management held 18,762 shares of Vertex Pharmaceuticals worth $8.73M as of Q3 2024.
Vertex Pharmaceuticals was a new Tri Ri Asset Management position in Q3 2024.
Vertex Pharmaceuticals made up 4.42% of Tri Ri Asset Management's portfolio in Q3 2024, its #7 holding.
1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Tri Ri Asset Management's 13F filing for Q3 2024, filed 21 Nov 2024.